Qnity

Name

Qnity

Legal name

Qnity Electronics Inc

Website

https://qnity.bio

Company type

Public

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Molecular Screening Technology

NAICS

Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)

SIC

Laboratory Analytical Instruments (3826)

akta.pro primary industry

Quantum Spectroscopy & Chemical/Biological Sensing (HDAGAHAH)

akta.pro secondary industries

Pharmaceutical & Biotech R&D Simulation (drug discovery, protein/ligand) (HDAGAEAB), Quantum Sensor Components & Subsystems (Lasers, Vacuum, Photonics, Diamond/NV, MEMS) (HDAGAHAM)

Keywords

• Molecular screening platform
• Drug discovery technology
• Quantum biosensing devices
• Biophysical binding analysis
• Electrochemical sensor chips

Headquarters

HQ city

São Paulo

HQ country

Brazil

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations

Revenue model

1. Semiconductor Materials Supply: Qnity Electronics Inc supplies materials used in semiconductor manufacturing, including CMP polishing pads for advanced chip processing. Revenue is generated through sales of materials to chip manufacturers.
2. Molecular Screening Technology: Qnity Bio provides molecular screening services and technology platforms to pharmaceutical companies and researchers for drug discovery applications.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Qnity builds and sells a quantum-electrochemical molecular screening platform centered on a proprietary custom chip with nanogold-silicon electrodes and quantum sensing technology. The device delivers ultra-sensitive drug discovery screening across all molecule sizes, from small organics to complex biologics, offering attomolar-level binding affinity detection and real-time kinetic analysis for pharmaceutical, biotech, and research laboratory customers.

Product overview

Qnity offers a single unified molecular screening platform centered on its proprietary quantum chip. The platform integrates one chip that handles all screening capabilities, delivering real-time molecular data with quantum-level precision for drug discovery applications. The system supports both macro molecule screening and small molecule screening use cases.

Differentiator

Problem solved

Functional benefit

Products and services

• Qnity Molecular Screening Platform A quantum-electrochemical device delivering ultra-sensitive drug discovery and screening across all molecule sizes, from small organics to complex biologics, built on a custom chip with nanogold-silicon electrodes and quantum sensing technology. Targets pharmaceutical companies, biotech firms, and research institutions for drug discovery and therapeutic development applications.

Quantifiable outcome

• Attomolar concentration sensitivity for binding affinity screening
• +1 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered core and supporting.

• SK hynixcoreStrategic or Co-development Partner · 16 October 2025Qnity Electronics (DuPont's electronics business) entered a strategic partnership with SK hynix to supply CMP polishing pads for semiconductor manufacturing. The partnership supports SK hynix's next-generation semiconductor processes and expands a long-standing relationship, ahead of Qnity's planned separation from DuPont in November 2025.
• LATAM to Tulsa - TLVcoreStrategic or Co-development PartnerSelected Qnity Bio to establish their U.S. headquarters in Tulsa, providing full soft-landing assistance, strategic investor access, potential customer connections, and non-dilutive funding.
• AbiquifisupportingStrategic or Co-development PartnerListed as a supporter organization, Brazilian quantum and advanced technology association supporting Qnity's initiatives.
• Apex BrasilsupportingStrategic or Co-development PartnerBrazilian trade and investment promotion agency listed as a supporter of Qnity.
• Hello Tomorrow Deep Tech PioneerssupportingStrategic or Co-development PartnerGlobal deep tech startup support organization recognizing and supporting Qnity.
• University of OxfordsupportingStrategic or Co-development PartnerOxford University and its Oxford University Innovation (OUI) arm listed as supporters, indicating research/academic partnership.
• World Economic ForumsupportingStrategic or Co-development PartnerListed as a supporter organization, indicating participation in global innovation and technology initiatives.

Scale indicators4 records

Recent moves9 records

Expansion highlights5 records

Broad incumbents

• Sartorius (Octet): Bio-layer interferometry (BLI) platform for high-throughput, label-free protein interaction and quantitation analysis. The Octet system is a direct substitute technology for the biophysical screening Qnity Bio's chip aims to perform.
• Thermo Fisher Scientific: Largest diversified scientific instrument and life-science tools vendor. Comparable in the analytical instrument category used for pharma/biotech R&D workflows where Qnity Bio's molecular screening platform would be deployed.
• Malvern Panalytical (MicroCal): Provides MicroCal isothermal titration calorimetry (ITC) instruments for measuring binding affinity, stoichiometry, and thermodynamics without labeling. A complementary incumbent technology in the biophysical characterization workflow Qnity Bio targets.
• Cytiva (Biacore): Global leader in surface plasmon resonance (SPR) instruments for label-free binding affinity and kinetics analysis used across pharma drug discovery. Biacore is the dominant incumbent in the molecular interaction analysis category Qnity Bio targets.
• Bruker: Major analytical instrument manufacturer with a broad portfolio spanning mass spectrometry, biophysical characterization, and life-science research tools. Overlaps with Qnity Bio in serving biophysical/binding analytics workflows for pharma and academic customers.

Direct peers

• Nicoya Lifesciences: Develops open-surface SPR and benchtop SPR instruments (Alto and OpenSPR) targeting more accessible, lower-cost kinetic analysis for academic and emerging biotech labs. Comparable as a smaller, technology-focused SPR/biophysics instrument vendor.
• Nanion Technologies: Specialist in high-throughput electrophysiology and binding kinetics platforms for drug discovery. Comparable as a smaller, technology-focused instrument vendor serving pharma/biotech R&D with novel biophysical measurement approaches.
• Carterra: High-throughput SPR platform purpose-built for antibody and biologics discovery, enabling rapid kinetic profiling of large panels. Most direct technology comparable in throughput-oriented binding kinetics for biologics — Qnity Bio's stated macro-molecule focus.

Regional players

• Quantum Design International: Developer of physical property measurement systems including platforms leveraging quantum sensing for materials characterization. Comparable as a vendor of quantum-enabled scientific instrumentation, though primarily focused on materials science rather than life sciences.

Emerging players

• QZabre (Quantum Diamond Technologies): Early-stage developer of quantum diamond (NV-center) sensors for nanoscale magnetic and chemical imaging. Comparable as a quantum-sensing technology company applying similar underlying physics principles to novel measurement applications.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Qnity